Growth Metrics

Thermo Fisher Scientific (TMO) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Thermo Fisher Scientific (TMO) over the last 17 years, with Q3 2025 value amounting to $2.9 billion.

  • Thermo Fisher Scientific's Current Deferred Revenue rose 709.73% to $2.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 709.73%. This contributed to the annual value of $2.9 billion for FY2024, which is 606.17% up from last year.
  • Thermo Fisher Scientific's Current Deferred Revenue amounted to $2.9 billion in Q3 2025, which was up 709.73% from $2.8 billion recorded in Q2 2025.
  • Thermo Fisher Scientific's Current Deferred Revenue's 5-year high stood at $2.9 billion during Q2 2022, with a 5-year trough of $1.4 billion in Q2 2021.
  • For the 5-year period, Thermo Fisher Scientific's Current Deferred Revenue averaged around $2.5 billion, with its median value being $2.7 billion (2021).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first surged by 10889.06% in 2021, then crashed by 727.97% in 2023.
  • Thermo Fisher Scientific's Current Deferred Revenue (Quarter) stood at $2.7 billion in 2021, then fell by 2.03% to $2.6 billion in 2022, then grew by 3.38% to $2.7 billion in 2023, then rose by 6.06% to $2.9 billion in 2024, then changed by 0.0% to $2.9 billion in 2025.
  • Its last three reported values are $2.9 billion in Q3 2025, $2.8 billion for Q2 2025, and $2.9 billion during Q1 2025.